Clinical Trial Search

Primary: Mean Number of Squamous Cell Carcinomas — 0.75; 1.00 # of squamous cell carcinomas — p=0.750

Primary: Toxicities Associated With Combined Radiotherapy and Erlotinib Treatments. — 15; 14; 12; 13 number of adverse events

Primary: Number of Participants With Objective Response (Partial Response, Stable Disease and Progressive Disease) — 14; 4; 19 participants

Primary: Objective Response Rate (ORR) — 4; 1; 1 Participants

Primary: Overall Response Rate — 3 Participants

Primary: Number of Subjects With Dose Limiting Toxicities — 0 Participants

Primary: Tissue and Hematopoietic Stem Cell Collection — 8 Participants

Primary: Cure Rate — 751 lesions

Primary: Objective Response Rate (Complete Response and Partial Response) — 0; 0 percentage of patients

Primary: Early Progression Rate — 31.8 percentage of participants

Primary: Number of Participants With Adverse Events — 10; 4; 1; 20 Participants

Primary: Overall Response Rate — 11; 1; 10 Participants — p=0.0005

Primary: Percentage of Participants With Local Regional Control — 91.1 percentage of subjects

Primary: Incidence of SCC — 3.1; 0.4 percentage of subjects

Primary: Number of Participants With Pathologic Complete Response (pCR) as Assessed by Independent Central Pathology Review — 40 Participants

Primary: The Time to Diagnosis of the First Keratinocyte Carcinoma (KC) on the Face or Ears for Which Surgery is Performed — 3.37; 3.52 years — p=0.93

Primary: Response Rate — .35; .22 proportion of participants

Primary: Number of Participants With High Grade (Grade 3, 4 and 5) Treatment Related Select Adverse Events — 1; 7; 0; 1 Participants

Primary: Number of Control and Intervention Participants on Skin Self-examination Performance at Follow-up 1 Month After Intervention — 34; 8 Participants

Primary: Skin Carotenoid Levels in Subjects With History of Squamous Cell Carcinoma Versus Control Subjects — 27,635; 31,219 Raman spectroscopy intensity counts — p=0.31

Primary: Number of Participants With at Least 20% Reduction of Buccal Micronuclei — 13 Participants

Primary: Percentage of Patients Free of Grade 3+ Late Toxicity — 86 percentage of participants

Primary: Percentage of Patients Who Complete Neoadjuvant Therapy and Were Eligible for Curative Surgical Resection — 16 Participants

Primary: Pathologic Response. — 25; 2; 4; 4 Participants

Primary: Change in Immune Response After Tadalafil Administration — 1.13; 1.59; 1.14; 4.74 fold change

Primary: Time on Treatment With Afatinib or Chemotherapy During Second Line (2L) Treatment — 7.3; 4.2 months

Primary: Change in Immune Response After Tadalafil Administration

Primary: Rate of Renal Transplant Rejection (Cohort 2) or GVHD (Cohort 1). — 0 Percentage of participants

Primary: Overall Response Rate — 18; 1; 5; 12 Participants

Primary: Complete Pathologic Response Rate — 6 Participants